Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs

被引:21
|
作者
Finlay, Andrea K. [1 ,2 ]
Ellerbe, Laura S. [1 ]
Wong, Jessie J. [1 ,3 ]
Timko, Christine [1 ,3 ]
Rubinsky, Anna D. [4 ,5 ]
Gupta, Shalini [1 ]
Bowe, Thomas R. [1 ]
Burden, Jennifer L. [6 ]
Harris, Alex H. S. [1 ,7 ]
机构
[1] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA
[2] Dept Vet Affairs, Natl Ctr Homelessness Vet, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA
[3] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 401 Quarry Rd, Menlo Pk, CA 94025 USA
[4] Univ Calif San Francisco, Kidney Hlth Res Collaborat, 500 Parnassus Ave, San Francisco, CA 94143 USA
[5] San Francisco VA Med Ctr, 500 Parnassus Ave, San Francisco, CA 94143 USA
[6] Vet Hlth Adm, Dept Vet Affairs, 1970 Roanoke Blvd,116A, Salem, VA 24153 USA
[7] Stanford Univ, Sch Med, Dept Surg, Alway Bldg,Room M121,300 Pasteur Dr, Stanford, CA 94305 USA
关键词
Alcohol-related disorders; Alcohol dependence; Pharmacotherapy; Veterans; Residential treatment; MENTAL-HEALTH; VETERANS; IMPLEMENTATION; DEPENDENCE; SETTINGS;
D O I
10.1016/j.jsat.2017.03.005
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Among US military veterans, alcohol use disorder (AUD) is prevalent and in severe cases patients need intensive AUD treatment beyond outpatient care. The Department of Veterans Affairs (VA) delivers intensive, highly structured addiction and psychosocial treatment through residential programs. Despite the evidence supporting pharmacotherapy among the effective treatments for AUD, receipt of these medications (e.g., naltrexone, acamprosate) among patients in residential treatment programs varies widely. In order to better understand this variation, the current study examined barriers and facilitators to use of pharmacotherapy for AUD among patients in VA residential treatment programs. Semi-structured qualitative interviews with residential program management and staff were conducted and the Consolidated Framework for Implementation Research was used to guide coding and analysis of interview transcripts. Barriers to use of pharmacotherapy for AUD included cultural norms or philosophy against prescribing, lack of access to willing prescribers, lack of interest from leadership, and perceived lack of patient interest or need. Facilitators included cultural norms of openness or active promotion of pharmacotherapy; education for patients, program staff and prescribers; having prescribers on staff, and care coordination within residential treatment and with other clinic settings in and outside VA. Developing and testing improvement strategies to increase care coordination and consistent support from leadership may also yield increases in the use of pharmacotherapy for AUD among residential patients. Published by Elsevier Inc
引用
收藏
页码:38 / 43
页数:6
相关论文
共 50 条
  • [31] Differences in Perceptions of and Practices Regarding Treatment of Alcohol Use Disorders Among VA Primary Care Providers in Urban and Rural Clinics
    Young, Jessica P.
    Achtmeyer, Carol E.
    Bensley, Kara M.
    Hawkins, Eric J.
    Williams, Emily C.
    JOURNAL OF RURAL HEALTH, 2018, 34 (04) : 359 - 368
  • [32] A Pilot Replication Study of Implementing an Equine-Assisted Services Program Within a VA Residential Substance Use Disorder Treatment Program
    Marchand, William R.
    Smith, Judy
    Nazarenko, Elena
    Joubert, Katryna
    Black, Heather
    Osborne, Makenna
    Andersen, Sarah
    Bell, Kylie
    Baldwin, Shannon
    Klinger, William
    Connelly, Heather
    Sheppard, Stephen
    Hoopes, Karl
    MILITARY MEDICINE, 2024, 189 (1-2) : e220 - e226
  • [33] Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use
    Hollander, Mara A. G.
    Chang, Chung-Chou H.
    Douaihy, Antoine B.
    Hulsey, Eric
    Donohue, Julie M.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 227
  • [34] Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden
    Mansson, Anastasia
    Danielsson, Anna-Karin
    Sjoqvist, Hugo
    Glatz, Toivo
    Lundin, Andreas
    Wallhed Finn, Sara
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2024, 19 (01):
  • [35] Facilitators and Barriers Associated With Mental Health Service Utilization Among Individuals With Alcohol Use Disorder in Korea
    Lee, Eun Sol
    Ha, Yujeong
    Ko, Young-Mi
    Park, Subin
    PSYCHIATRY INVESTIGATION, 2025, 22 (01) : 1 - 9
  • [36] Receipt of pharmacotherapy for alcohol use disorder by justice-involved women in the Veterans Health Administration
    Emmeline Taylor
    Christine Timko
    Alex H. S. Harris
    Mengfei Yu
    Andrea K. Finlay
    Addiction Science & Clinical Practice, 14
  • [37] Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review
    Turna, Jasmine
    Syan, Sabrina K.
    Frey, Benicio N.
    Rush, Brian
    Costello, Mary Jean
    Weiss, Mark
    MacKillop, James
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 43 (04): : 550 - 563
  • [38] Implementation of Smoking Cessation Treatment in VHA Substance Use Disorder Residential Treatment Programs
    Gifford, Elizabeth
    Tavakoli, Sara
    Wisdom, Jennifer
    Hamlett-Berry, Kim
    PSYCHIATRIC SERVICES, 2015, 66 (03) : 295 - 302
  • [39] Delay to first treatment contact for alcohol use disorder
    Chapman, Cath
    Slade, Tim
    Hunt, Caroline
    Teesson, Maree
    DRUG AND ALCOHOL DEPENDENCE, 2015, 147 : 116 - 121
  • [40] Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis
    Rogal, Shari
    Youk, Ada
    Zhang, Hongwei
    Gellad, Walid F.
    Fine, Michael J.
    Good, Chester B.
    Chartier, Maggie
    DiMartini, Andrea
    Morgan, Timothy
    Bataller, Ramon
    Kraemer, Kevin L.
    HEPATOLOGY, 2020, 71 (06) : 2080 - 2092